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Policy Forum
What Is Therapeutic 
Misconception?
For over three decades, bioethics 
scholarship and research ethics 
guidelines have identiﬁed concerns 
about the boundaries between 
research and standard clinical care 
[1,2]. Ethicists have argued that 
informed consent to participate in 
research should include clariﬁcation 
of the differences between these two 
activities [3–10]. In 1982, Appelbaum 
and colleagues reported on ﬁndings 
from interviews with patients with 
psychiatric disorders that documented 
failure to appreciate the difference 
between research and treatment, 
labeling the phenomenon “therapeutic 
misconception” (TM) [3].
Despite considerable empirical 
research on TM in the intervening 
years, a consistent deﬁnition has not 
emerged in the literature. Without such 
a deﬁnition, meaningful empirical work 
to measure and assess the prevalence of 
TM, or to test interventions to reduce 
it, is difﬁcult to conduct. Progress is 
further impeded when studies use 
measures that reﬂect inconsistent 
deﬁnitions of research and clinical 
care, which are fundamental to the 
deﬁnition of TM.
Scholars who have contributed to 
this literature, including this paper’s 
authors, met at the University of North 
Carolina at Chapel Hill in September 
2005 to address the debate on 
deﬁning TM. The workshop included 
a University of North Carolina team 
funded to study TM in early-phase gene 
transfer research (R01 HG 02087) 
[11–17] and others from the ﬁelds of 
medicine, oncology, public health, 
sociology, philosophy, anthropology, 
law, and bioethics. Following guidelines 
on scale development [18], we debated 
deﬁnitions based on the literature, 
evaluated questions that could be 
used in a TM scale, and participated 
in ongoing discussion during the 
following year. In this article, we 
summarize the controversies, propose 
a deﬁnition with speciﬁc dimensions, 
and describe how these dimensions can 
be operationalized to produce a valid 
measure of TM.
Defining Therapeutic 
Misconception
In Appelbaum and colleagues’ study 
[3], the patients interviewed were 
enrolled in clinical trials that involved 
randomization, non-treatment control 
groups and placebos, and double-blind 
procedures. The researchers found that 
many trial participants were unaware 
of study design implications, especially 
random assignment to a control or 
comparison group, often believing that 
they were assigned a medication based 
on what was best for them, personally. 
The authors concluded that those 
patients who are trial participants and 
who do not adequately appreciate 
the purpose and methods of research 
studies are ill-equipped to evaluate risks 
and beneﬁts of study participation, and 
may fail “to recognize how personal 
care may be compromised by research 
procedures” [19].
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Summary Points
• A key component of informed consent 
to participate in medical research is the 
understanding that research is not the 
same as treatment.
• However, studies have found that 
some research participants do not 
appreciate important differences 
between research and treatment, 
a phenomenon called “therapeutic 
misconception.”
• A consistent definition of therapeutic 
misconception is missing from the 
literature, and this hinders attempts to 
define its prevalence or ways to 
reduce it.
• This paper proposes a new definition 
and describes how it can be 
operationalized.
The Policy Forum allows health policy makers around 
the world to discuss challenges and opportunities for 
improving health care in their societies.
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Confusion about the purpose of 
research is integral to most deﬁnitions 
of TM. According to Appelbaum 
and colleagues, TM occurs “when a 
research subject fails to appreciate the 
distinction between the imperatives 
of clinical research and of ordinary 
treatment, and therefore inaccurately 
attributes therapeutic intent to 
research procedures” [6]. In 2001, 
the National Bioethics Advisory 
Commission (NBAC) deﬁned TM 
similarly, as “the belief that the purpose 
of a clinical trial is to beneﬁt the 
individual patient rather than to gather 
data for the purpose of contributing to 
scientiﬁc knowledge” [5].
In its report, NBAC called attention 
to the important distinction between 
the purpose of research as a knowledge-
generating activity and its broader 
consequences, which may include 
potential beneﬁt from the intervention 
(direct beneﬁt) or from other aspects 
of study participation (inclusion or 
collateral beneﬁt) [20,21]. The report 
stated, “It is not a misconception to 
believe that participants probably 
will receive good clinical care during 
research. But it is a misconception to 
believe that the purpose of clinical trials 
is to administer treatment rather than to 
conduct research” [5]. Joffe and Miller 
[22], citing Levine [23] among others, 
point out that regardless of the potential 
for beneﬁt to participants, research is 
always conducted in order to achieve 
scientiﬁc goals and contribute to 
generalizable knowledge [24]. Research 
participants who misunderstand this 
key point may not be able to make 
meaningful decisions to enroll in a 
clinical trial. Even participants who 
beneﬁt, and who suffer little or no 
physical harm, may be wronged if they 
lack information essential to their 
decisions. Such non-physical harms 
or wrongs are called dignitary injuries 
(see a recent exchange [25,26] on the 
importance of this issue).
Some consider overestimation of 
clinical beneﬁt from an experimental 
intervention, as well as underestimation 
of potential risk of harm [27], to 
be part of TM. Concern about the 
tendency to overestimate beneﬁt 
has been prominent in discussions 
of early-phase cancer trials as well as 
other studies in which the likelihood 
of direct beneﬁt is low, or in which 
the design (e.g., placebo-controlled 
trials) precludes direct beneﬁt from 
an intervention for at least some 
participants [11,19,28–31]. Yet 
not all agree with the premise that 
overestimation of direct beneﬁt from 
an experimental intervention is part 
of TM. Horng and Grady [32] argue 
that this phenomenon is different from 
and not integral to misunderstanding 
the nature and scientiﬁc intent of 
research. In addition, the extreme 
heterogeneity of clinical trial design 
makes generalizations about realistic 
expectation of direct beneﬁt very 
difﬁcult.
Problems in Measuring TM
Since the original publication on TM 
[3], a number of empirical studies 
have explored the motivations, 
understandings, and expectations of 
patients who participate in research. 
Researchers have asked such questions 
as: Why do patients join a study? What 
is their understanding and recollection 
of the purpose of the research and 
particular aspects of study design? Can 
they differentiate the goals of research 
from those of clinical care? What are 
their expectations about the likelihood 
of direct beneﬁt? These studies have 
used closed-ended questionnaires 
analyzed quantitatively [33], open-
ended interviews analyzed qualitatively, 
or both [11,19]. Some studies included 
questions relevant to TM as part of 
a general investigation of ethical 
dilemmas in clinical trials, whether 
they set out to study TM [34] or not 
[31,35,36].
But with only a few exceptions 
[29,34,37], these studies did not use 
standardized questions and did not 
attempt to validate measures of TM 
or related constructs. Nor, with one 
notable exception [38], did they 
explore measurement issues such as 
how people understand the terms 
“research,” “treatment,” “experimental 
intervention,” or “study purpose.” 
Studies of issues relevant to 
TM, which often use small, non-
random samples, have documented 
misunderstanding among research 
participants related to characteristics 
such as older age, lower education, and 
the way in which information about the 
study is conveyed [11,19,33,34]. Only a 
few studies have included participants 
from different types of trials. For 
example, Henderson and colleagues 
[11] used a non-validated TM measure 
based on responses to interview 
questions about study purpose, reasons 
for participation, and expectations of 
direct beneﬁt. They found that among 
participants in early-phase gene transfer 
research trials, those in trials for HIV 
and genetic disease had signiﬁcantly 
lower scores on a composite TM scale 
than those in oncology or vascular 
disease trials. Nonetheless, because 
empirical investigations of TM have 
been undertaken without a consensus 
deﬁnition or consistent measures, the 
interpretation and comparability of 
such ﬁndings are in question, as are 
their implications for improving the 
informed consent process in clinical 
research.
One reason for uncertainty about 
the deﬁnition of TM is disagreement 
about what research participants ought 
to understand about the purpose of 
clinical research. There is consensus 
that they should understand that 
research has scientiﬁc goals. However, 
there are differences regarding 
what should be understood about 
therapeutic goals in clinical research.
Clinical investigators themselves hold 
different views on this issue [12,39]. 
In a recent survey of oncologists, Joffe 
and Weeks [7] found that 20% viewed 
the “main societal purpose of research” 
as ensuring state-of-the-art therapy for 
participants. This response may reﬂect 
underlying tension about the moral 
justiﬁcation of research: that subjecting 
patients to potentially risky research 
is unethical unless clinical beneﬁt is a 
legitimate research purpose [10]. In 
contrast, many bioethicists and clinical 
investigators ﬁnd this view problematic 
because it confounds the purpose of 
research with its possible consequences 
[7,12,39,40].
An Example of the Difficulty in 
Defining TM
Discordance in the literature on 
TM was reﬂected in our workshop 
Box 1. Definition of Therapeutic 
Misconception
Therapeutic misconception exists 
when individuals do not understand that 
the defining purpose of clinical research 
is to produce generalizable knowledge, 
regardless of whether the subjects 
enrolled in the trial may potentially 
benefit from the intervention under study 
or from other aspects of the clinical trial.
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discussions of the purpose of a research 
study. We considered whether the 
following question could be part of an 
instrument designed to measure TM:
“The purpose of the study is:
(1) Only to help patients enrolled in 
the study, or
(2) Both to help patients enrolled in 
the study and patients in the future, or
(3) Only to help patients in the 
future”
There was consensus that 
answer (1) is incorrect and reﬂects 
misunderstanding of the purpose 
of research studies, but there was 
disagreement about whether the 
correct answer was (2) or (3). Those 
who argued that (3) is the only correct 
response believe that the purpose of 
a trial is to further science and help 
future patients, not to help the patients 
enrolled in the study. According to 
this argument, the purpose of an 
experimental intervention is not to 
provide treatment (i.e., clinical trials 
are not treatment). The presence 
of concomitant clinical care and 
the potential for beneﬁt associated 
with trial participation should not 
be confused with the fundamentally 
scientiﬁc goals of clinical trials.
In contrast, advocates of (2) as the 
correct response believe that helping 
patients enrolled in a study can be a 
legitimate additional study purpose. 
This may be because research and 
clinical care procedures and activities 
overlap, or because administration of 
an experimental agent is seen both 
as a means to learn about its safety 
and efﬁcacy and as an appropriate 
therapeutic option. This conceptual 
debate reveals the difﬁculty of applying 
general assessments to trials that 
employ very different study designs. It is 
also relevant to recent empirical efforts 
to clarify whether or not participation 
in a clinical trial is associated with 
improved outcomes for participants 
[41–43].
A New Definition of TM
Amid the controversies, there 
is consensus that the defining
characteristic of research is to create 
generalizable knowledge through 
answering a scientiﬁc question. There 
is disagreement, however, regarding 
which elements of a trial could 
plausibly have a therapeutic purpose, 
whether additional therapeutic beneﬁt 
ought to be counted as a study purpose,
and whether overestimation of direct 
clinical beneﬁt is part of TM.
To move beyond this impasse, we 
propose a consensus deﬁnition of TM 
that focuses on understanding the 
defining scientiﬁc purpose of research, 
irrespective of whether there are 
other reasonable goals. This deﬁnition 
acknowledges the important potential 
for clinical beneﬁt and recognizes that 
opinions vary about whether and how 
clinical care and therapeutic purpose 
are combined with research. While 
the literature on TM has focused on 
patients who participate in research 
as the group most vulnerable to 
possible harm, Dresser [10] and others 
[7,12,44] have shown that TM is not 
limited to research participants. Thus 
our consensus deﬁnition is framed in 
terms general enough to be relevant to 
researchers, members of institutional 
review boards (research ethics 
committees), and others.
Finally, our deﬁnition (Box 1) 
does not include overestimation of 
the possible beneﬁcial consequences 
of an experimental intervention. It 
is true that in many cases, TM may 
lead to overestimation of beneﬁt, 
underestimation of risk of harm, or 
underappreciation of alternatives to 
participation. However, we argue that 
none of these results is a necessary 
consequence of TM; each could arise 
independently and coexist with an 
adequate understanding of the purpose 
of research.
In order to develop speciﬁc questions 
to assess TM, we have identiﬁed ﬁve 
draft dimensions of research that 
individuals should understand, listed 
in Box 2. Using these dimensions, 
speciﬁc questionnaire items can be 
developed, tested for understandability, 
and ultimately combined to produce 
a composite measure of TM [18]. 
For example, questions based on the 
Scientiﬁc Purpose dimension, with 
agree–disagree or true–false responses, 
might include: “This study has been 
designed only to improve the health of 
the patients enrolled in it” and “If the 
experimental treatment is not effective, 
then the study is a failure.” Questions 
based on the Study Procedures 
dimension might include: “Procedures 
that have no beneﬁt to patients in the 
study may still be done for scientiﬁc 
purposes” and “Every procedure in 
the study is designed only to help the 
patients in it.”
While our deﬁnition and draft 
dimensions are applicable across 
populations and studies, questions 
about TM should be tailored to the 
experiences of particular groups (e.g., 
participants or researchers). Within-
group differences, such as those 
between patients participating in trials 
with different designs, may also require 
the use of tailored questions (e.g., 
trials only evaluating safety versus those 
with efﬁcacy objectives). Discussion 
continues as we seek dimensions 
that apply to all clinical trials. Such 
discussion will require input from 
a variety of experts, including trial 
investigators, to be sure that these 
dimensions apply to diverse situations.
Dimension 1. Scientific Purpose
Clinical research is designed to produce 
generalizable knowledge and to answer 
questions about the safety and efficacy 
of intervention(s) under study in order to 
determine whether or not they may be 
useful for the care of future patients.
Dimension 2. Study Procedures
Participation in a trial may involve 
procedures or tests, in addition to the 
intervention(s) under study, that are 
intended only or primarily to generate 
scientific knowledge and that are 
otherwise not necessary for patient care.
Dimension 3. Uncertainty
For intervention(s) under study in 
clinical research, there often is less 
knowledge and more uncertainty about 
the risks and benefits to a population 
of trial participants than there is when 
a doctor offers a patient standard 
interventions.
Dimension 4. Adherence to Protocol
Administration of the intervention(s) 
under study is typically based on a strict 
protocol with defined dose, scheduling, 
and use or avoidance of concurrent 
medications, compared to administration 
of standard interventions.
Dimension 5. Clinician as Investigator
Clinicians who are in health care settings 
provide treatment; in a clinical trial 
setting, they are also investigating safety 
and efficacy of an intervention.
Box 2. Five Draft Dimensions of Research that Should Be 
Understood by Trial Participants
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Implications for Future Research
Reﬁning the standard measurement 
of TM will provide a means to assess 
research understanding in different 
types of clinical trials and study 
populations. Such a tool can serve 
both to improve the protection of trial 
participants and reﬁne the informed 
consent process, aiding accrual to 
clinical trials through a process that 
is both effective and efﬁcient [15]. 
Historically, research on TM has been 
motivated by concern that participants 
may misunderstand aspects of trial 
care that lead them to make decisions 
incompatible with their true preferences 
and values. Though participants may 
recognize they are in a trial, failure to 
understand how care received during 
a trial can differ from standard care, 
and confusion over the purpose of 
these distinct activities, can compromise 
informed consent to research 
participation. While debate over other 
important aspects of informed consent 
is likely to continue, progress can be 
made in measuring TM by limiting 
our attention to those aspects that 
clearly interfere with trial participants’ 
decision-making through failure to 
understand the deﬁning nature and 
purpose of clinical research. 
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